This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Graphite Bio Croissance future

Future contrôle des critères 0/6

Graphite Bio devrait augmenter ses bénéfices de 36.4% par an. Le BPA devrait augmenter de 73.8% par an.

Informations clés

36.4%

Taux de croissance des bénéfices

73.8%

Taux de croissance du BPA

Biotechs croissance des bénéfices	27.3%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	15 Nov 2023

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:GRPH - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-23	N/A	N/A	1
12/31/2025	N/A	-23	N/A	N/A	1
12/31/2024	N/A	-23	N/A	N/A	1
12/31/2023	N/A	-125	-101	-90	N/A
9/30/2023	N/A	-126	-78	-67	N/A
6/30/2023	N/A	-129	-87	-79	N/A
3/31/2023	N/A	-99	-92	-88	N/A
12/31/2022	N/A	-101	-95	-88	N/A
9/30/2022	N/A	-95	-88	-81	N/A
6/30/2022	N/A	-85	-84	-74	N/A
3/31/2022	N/A	-77	-75	-66	N/A
12/31/2021	N/A	-71	-59	-53	N/A
9/30/2021	N/A	-115	-48	-43	N/A
6/30/2021	N/A	-104	-32	-30	N/A
3/31/2021	N/A	-88	-19	-17	N/A
12/31/2020	N/A	-68	-10	-9	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: GRPH devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: GRPH devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: GRPH devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de GRPH devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: GRPH ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de GRPH devrait être élevé dans 3 ans

This company is no longer active

Graphite Bio Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 23% to US$2.83

Price target decreased to US$10.86

Recent updates

Graphite Bio, Inc.(NasdaqGM:GRPH) dropped from NASDAQ Composite Index

New major risk - Share price stability

Graphite Bio, Inc. Declares Special Dividend, Payable on March 21, 2024

Graphite Bio, Inc. Declares Special Dividend, Payable on March 21, 2024

LENZ Therapeutics, Inc. entered into a definitive merger agreement to acquire Graphite Bio, Inc. (NasdaqGM:GRPH) for approximately $230 million in a reverse merger transaction.

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Graphite Bio, Inc. Announces Executive Changes

Graphite Bio, Inc. Appoints Kimberlee C. Drapkin as Independent Director

Graphite Bio, Inc Announces Departure of Alethia Young as Chief Financial Officer

Graphite Bio, Inc., Annual General Meeting, Jul 19, 2023

We're Hopeful That Graphite Bio (NASDAQ:GRPH) Will Use Its Cash Wisely

Price target decreased by 23% to US$2.83

Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?

Graphite Bio, Inc. Announces Voluntary Pause of Phase 1/2 Cedar Study of Nulabeglogene Autogedtemcel (Nula-Cel) for Sickle Cell Disease

Price target decreased to US$10.86

Graphite Bio, Inc. Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting

High number of new and inexperienced directors

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Graphite Bio, Inc. Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease

Graphite Bio doses first patient with GPH101 for sickle cell disease

Graphite Bio, Inc.(NasdaqGM:GRPH) dropped from Russell 2500 Value Index

Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?

Graphite Bio: Selling For Much Less Than Net Cash

Graphite Bio, Inc. Presents Preclinical Gene Replacement Data for GPH102 for Beta-Thalassemia at the ASGCT 25 Annual Meeting

Graphite Bio, Inc., Annual General Meeting, Jun 21, 2022

High number of new and inexperienced directors

Graphite Bio, Inc. Announces Management Changes

Graphite Bio, Inc. Announces Executive Changes

High number of new and inexperienced directors

Graphite Bio, Inc. Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition

Graphite Bio: An Important Stock To Track In The Gene Editing Space

Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans

Graphite Bio: Assessing Prospects Amid Doubts Raised On Safety Of Crispr

Graphite Bio, Inc. has completed an IPO in the amount of $238 million.

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance